<DOC>
	<DOCNO>NCT00521014</DOCNO>
	<brief_summary>RATIONALE : Giving high-dose chemotherapy autologous stem cell transplant help stop growth cancer cell stop divide kill . An autologous stem cell transplant may able replace blood-forming cell destroy chemotherapy . GM-CSF may increase number immune cell find bone marrow peripheral blood . Giving monoclonal antibody , rituximab , transplant may find remain cancer cell either kill deliver cancer-killing substance without harm normal cell . Giving GM-CSF together rituximab autologous stem cell transplant may effective treatment follicular non-Hodgkin lymphoma . PURPOSE : This phase II trial study well give GM-CSF together rituximab autologous stem cell transplant work treat patient relapse primary refractory follicular non-Hodgkin lymphoma .</brief_summary>
	<brief_title>GM-CSF Rituximab After Autologous Stem Cell Transplant Treating Patients With Relapsed Refractory Follicular Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess progression-free survival rate 2 year autologous stem cell transplantation ( ASCT ) patient relapse primary refractory follicular lymphoma treat sargramostim ( GM-CSF ) rituximab ASCT . Secondary - To assess safety administer GM-CSF rituximab ASCT . - To assess effect GM-CSF relative expression activate inhibitory FcγR circulating monocyte . - To assess effect GM-CSF relative expression activate inhibitory FcγR circulate dendritic cell . - To assess effect GM-CSF level circulate FcγR . - To assess reconstitution NK cell , NK-T cell , dendritic cell subset , regulatory T-cells ASCT . OUTLINE : - High-dose chemotherapy : Patients receive carmustine IV 2 hour day -7 , etoposide IV 1 hour cytarabine IV every 12 hour day -6 -3 , melphalan IV day -2 . - Autologous stem cell transplantation ( ASCT ) : Patients undergo ASCT day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) day begin day 5 continue blood count recover . - Sargramostim ( GM-CSF ) rituximab : Beginning approximately 7-10 week ( 49-70 day ) ASCT , patient receive GM-CSF SC 3 time week 8 week rituximab IV weekly 4 week ( begin within 3 day first dose GM-CSF ) . Patients receive second course GM-CSF rituximab ( ) begin approximately 22-26 week ( 154-182 day ) ASCT . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic diagnosis grade 1 , 2 , 3 , transform follicular lymphoma Achieved complete partial response last salvage therapy Completed salvage therapy within past 12 week No disease progression since last salvage therapy One follow disease status must present prior receive salvage therapy Refractory last antilymphoma therapy Last remission duration le 1½ year salvage therapy 3rd regimen Last remission duration le 3 year salvage therapy 2nd regimen Minimum 2 x 10^6 CD34+ cells/kg cryopreserved available hematopoietic stem cell support No leptomeningeal disease brain parenchyma involvement PATIENT CHARACTERISTICS : Cardiac ejection fraction &gt; 50 % If 60 year age , evidence cardiac ischemia treadmill stress test ( stress echo sestaMIBI ) Adjusted diffuse capacity ≥ 50 % predict value pulmonary function test Creatinine ≤ 1.5 mg/dL OR creatinine clearance &gt; 50 mL/min ANC &gt; 1,000/μL Platelet count &gt; 50,000/μL Total bilirubin ≤ 2.0 mg/dL ( ≤ 3.0 mg/dL Gilbert 's disease suspect ) Not pregnant breastfeed Fertile patient must use acceptable form birth control HIV I II negative No acute chronic hepatitis B No active hepatitis C No medical illness ( unrelated nonHodgkin lymphoma ) , include malignancy , opinion attend physician and/or principal investigator , would preclude study treatment No malignancy within past 5 year except curatively treat cutaneous basal cell squamous cell carcinoma carcinoma situ cervix PRIOR CONCURRENT THERAPY : No 3 prior antilymphoma regimen , inclusive salvage therapy Biologic agent ( e.g. , monoclonal antibody vaccine ) administer part plan treatment regimen consider distinct regimen Chemotherapy administer primarily purpose stem cell mobilization ( e.g. , cyclophosphamide 24 g/m² ) consider antilymphoma regimen No prior autologous allogeneic hematopoietic stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>